缩写名/全名 |
TARGET ONCOL
Targeted Oncology |
||||||||||||||||||||||||
ISSN号 | 1776-2596 | ||||||||||||||||||||||||
研究方向 | 医学-肿瘤学 | ||||||||||||||||||||||||
影响因子 | 2015:3.197, 2016:3.438, 2017:3.877, 2018:3.683, 2019:4.036, | ||||||||||||||||||||||||
出版国家 | FRANCE | ||||||||||||||||||||||||
出版周期 | Quarterly | ||||||||||||||||||||||||
年文章数 | 68 | ||||||||||||||||||||||||
出版年份 | 2006 | ||||||||||||||||||||||||
是否OA | No | ||||||||||||||||||||||||
审稿周期(仅供参考) | >12周,或约稿 |
||||||||||||||||||||||||
录用比例 | 较易 | ||||||||||||||||||||||||
投稿链接 | https://www.editorialmanager.com/targ/default.aspx | ||||||||||||||||||||||||
投稿官网 | http://www.springer.com/medicine/internal/journal/11523 | ||||||||||||||||||||||||
h-index | 35 | ||||||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=1776-2596%5BISSN%5D | ||||||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | Distribution of <Emphasis Type="Italic">ALK</Emphasis> Fusion Variants and Correlation with Clinical Outcomes in Chinese Patients with Non-Small Cell Lung Cancer Treated with Crizotinib Author: Yudong Su, Xiang Long, Yang Song, Peng Chen, Shanqing Li, Huaxia Yang, Pancheng Wu, Yanyu Wang, Zhongxing Bing, Zhili Cao, Lei Cao, Yijun Wu, Zhe Zhang, Jing Liu, Bing Li, Jianxing Xiang, Ke Ma, Tengfei Zhang, Lu Zhang, Xinru Mao, Hao Liu, Puyuan Xing, Naixin Liang Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00631-x DOI |
2. | Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study Author: Xiaonan Hong, Yuqin Song, Huiqiang Huang, Bing Bai, Huilai Zhang, Xiaoyan Ke, Yuankai Shi, Jun Zhu, Guodong Lu, Stefan Liebscher, Chunxiao Cai Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00630-y DOI |
3. | Clinical Management of Non-Small Cell Lung Cancer with Concomitant <Emphasis Type="Italic">EGFR</Emphasis> Mutations and <Emphasis Type="Italic">ALK</Emphasis> Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib Author: Yiming Zhao, Shuyuan Wang, Bo Zhang, Rong Qiao, Jianlin Xu, Lele Zhang, Yanwei Zhang, Baohui Han Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00628-6 DOI |
4. | Serum Alpha1-Globulin as a Novel Prognostic Factor in Metastatic Renal Cell Carcinoma Treated with Tyrosine Kinase Inhibitors Author: Xiang Chen, JiaXi Yao, Li Liu, WenZhong Zheng, XiaoYi Hu, YanJun Zhu, Hang Wang, JianMing Guo Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-019-00625-9 DOI |
5. | Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy Author: Zhuanglin Li, Mingxue Wang, Xuejing Yao, Wenting Luo, Yaocheng Qu, Deling Yu, Xue Li, Jianmin Fang, Changjiang Huang Journal: Targeted Oncology, 2019, Vol., , DOI:10.1007/s11523-018-0616-8 DOI |
6. | Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy Author: Xia Yang, Jia Rao, Wentao Yang, Ruohong Shui Journal: Targeted Oncology, 2018, Vol.13, 757-767, DOI:10.1007/s11523-018-0602-1 DOI |
7. | Comparison of the efficacy and safety of single-agent erlotinib and doublet molecular targeted agents based on erlotinib in advanced non-small cell lung cancer (NSCLC): a systematic review and meta-analysis Author: Gaofeng Pan, Shaobo Ke, Jinping Zhao Journal: Targeted Oncology, 2013, Vol.8, 107-116, DOI:10.1007/s11523-013-0272-y DOI |
8. | Hyperbaric oxygen and cancer: more complex than we expected Author: Liu Wenwu, Sun Xuejun, Tao Hengyi, Liu Kan Journal: Targeted Oncology, 2013, Vol.8, 79-81, DOI:10.1007/s11523-013-0259-8 DOI |
9. | Prognostic Role of Programmed Death Ligand-1 Expression in Breast Cancer: A Systematic Review and Meta-Analysis Author: Xue Li, Minghuan Li, Zhen Lian, Hui Zhu, Li Kong, Ping Wang, Jinming Yu Journal: Targeted Oncology, 2016, Vol.11, 753-761, DOI:10.1007/s11523-016-0451-8 DOI |
10. | RETRACTED ARTICLE: MicroRNA-216b is Down-Regulated in Human Gastric Adenocarcinoma and Inhibits Proliferation and Cell Cycle Progression by Targeting Oncogene HDAC8 Author: Ying Wang, Po Xu, Jun Yao, Ruina Yang, Zhenguo Shi, Xiaojuan Zhu, Xiaoshan Feng, Shegan Gao Journal: Targeted Oncology, 2015, Vol.11, 197-207, DOI:10.1007/s11523-015-0390-9 DOI |
|
|